Search

Displaying results 4491 - 4500 of 9333 in total
  1. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    The elicited antibodies are highly specific and able to inhibit the parasite’s ability to invade liver tissue _in vitro_. … The two synthetic peptide vaccine components mimic the native structure of important antigens of the malaria parasite.

  2. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    Bupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

  3. Drug

    Cycloguanil

    go.drugbank.com/drugs/DB14763
    Approved

    Cycloguanil is the active metabolite of [proguanil].

  4. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  5. Drug

    LNP-nCoVsaRNA Vaccine

    go.drugbank.com/drugs/DB15799
    Experimental

    LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. … As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity of the vaccine.

  6. Drug

    3-Fluoro-L-tyrosine

    go.drugbank.com/drugs/DB04436
    Experimental

    This compound belongs to the phenylpropanoic acids. … These are compounds whose structure contain a benzene ring conjugated to a propanoic acid. 3-Fluoro-L-tyrosine targets the protein superoxide dismutase [mn], mitochondrial.

  7. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  8. Drug

    IMCY-0141

    go.drugbank.com/drugs/DB17019
    Investigational

    IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin … sheath protecting the nerves.

  9. Drug

    Risvutatug rezetecan

    go.drugbank.com/drugs/DB23560
    Investigational

    That Cannot be Surgically Removed). … It is under investigation in clinical trial NCT06885034 (A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers

  10. Drug

    Maplirpacept

    go.drugbank.com/drugs/DB18441
    Investigational

    Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.